Highly active antiretroviral therapy (HAART) decreases the plasma virus load and increases CD4
+ T lymphocyte counts in patients infected with human immunodeficiency virus (HIV) type 1 [1] [2] [3] . There is also evidence of immune reconstitution in some of these patients [4] . Although immune responses against opportunistic infections in general recover, whether recovery of HIV-1-specific immune responses occurs has been controversial. Immediate treatment of acute HIV-1 infection with HAART sustains HIV-1-specific cytotoxic T lymphocyte responses [5] . By contrast, HIV-1-specific cytotoxic T lymphocyte responses decline as the virus is suppressed in patients who undergo HAART during chronic infection [6] [7] [8] [9] . These differences reflect the lack of HIV-specific T helper functions for the maintenance of CD8 + T cell responses [10, 11] .
Humoral immunity against HIV-1 infection in a different clinical setting has been reported. Patients experiencing longterm nonprogression (LTNP) have a broad range of neutralizing antibodies against both autologous and heterologous primary isolates [12] .
In untreated patients, envelope-specific antibody is usually detected within 10 weeks after infection [13] [14] [15] . However, development of neutralizing antibodies against autologous isolates is delayed in most patients, and neutralization activities are generally weak [12, 13, 16, 17] . On the other hand, a recent study by Ruppach et al. [18] found that neutralization activities against autologous isolates were detectable shortly after seroconversion when primary macrophages were used as target cells.
In many patients undergoing HAART during acute HIV-1 infection, neutralizing antibody responses against autologous isolates are relatively weak and slow to develop [12, 16] . The envelope-specific antibody titer is generally low and reduced, compared with pre-HAART titers, in these patients [16, 19] .
Among patients for whom HAART was initiated during chronic infection, the HIV-1-specific binding antibody response is generally reduced during HAART, even if the response was well developed before the start of HAART [19] . The effects of HAART in chronically infected patients with regard to neutralizing antibody responses against autologous isolates are poorly understood. When we investigated longitudinal changes in the neutralization activity of IgG against autologous isolates from patients who were treated with HAART, we obtained evidence for reconstitution of or increase in spontaneous neutralization activity in 4 of 19 chronically infected patients.
Subjects, Materials, and Methods
Study subjects. All of the HIV-1-seropositive Japanese patients we treated were followed up at Kumamoto University Hospital, Kumamoto, Japan. Nineteen patients who had been infected for a range of 3-15 years (chronic infection) and had not received HAART were included in this study (table 1) . HAART was defined as a combination of a minimum of 3 drugs that included 1 or 2 reverse-transcriptase inhibitors and at least 1 protease inhibitor of HIV-1. Thirteen of the 19 patients were given 1 or 2 reversetranscriptase inhibitors before the initiation of HAART. Patients who were seropositive for HIV-1, were asymptomatic, and had stable levels of CD4 + T lymphocytes (.600 lymphocytes/mL) and an undetectable level of plasma HIV RNA (,50 copies/mL) that were maintained without other therapy for .10 years were considered to have LTNP.
Virus isolates, reagents, and ELISA. HIV-1 strains JR-FL (macrophage tropic; R5), SF162 (R5), and NL4-3 (T cell tropic; X4) were propagated in PM1 cells in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (complete medium), and cell-free supernatants collected as virus stocks were stored at 280 C. A primary isolate (KMT) was obtained from an HIV-1-infected patient, as described elsewhere [20] , that uses both CXCR4 and CCR5 [21] .
The humanized monoclonal antibodies RC25 (unpublished clone) and Cb1 [22, 23] were developed as anti-V3 loop neutralizing antibodies. RC25 recognizes the (I)GPGRA sequence, and Cb1 recognizes the IQRGPGRA sequence. RC25 has strong neutralization activity against JR-FL and weak activity against NL4-3; Cb1 has strong neutralization activity against NL4-3 and no activity against JR-FL.
We investigated, using ELISA, the ability of patients' plasma to bind to monomeric recombinant gp120 or solid-phase peptide. The plasma samples were diluted to 1:300. Recombinant gp120 from SF162 and NL4-3 [24] was a gift from Y. Nagai (AIDS Research Center, National Institute of Infectious Disease, Tokyo, Japan). V2 and V3 loop peptides from patients 17 and 19 were obtained from Asahi Techno Glass.
Detection of antigen-specific CD4 + T cells. To assess antigenspecific CD4 + T cells, we used a protocol based on intracytoplasmic staining of cytokines in short term-activated secretion-inhibited T cells and multiparameter flow cytometric analysis [25] . Flow cytometric analysis was done on FACSCalibur (Becton Dickinson). Samples of peripheral blood mononuclear cells (PBMC) from all patients were prepared at the end of study. A heat-inactivated virus stock of JR-FL served as the HIV antigen, at a final concentration of 100 ng/mL of p24. The HIV-specific CD4 + T cell frequencies measured in 5 seronegative volunteers were ,0.02%. Therefore, we defined a CD4 + T cell frequency of .0.1% as an HIVspecific response.
Primary virus isolation. PBMC were obtained from HIV-1-infected patients and prepared by gradient centrifugation on Ficoll- NOTE. A slash between drug names indicates that agents were used in combination; a comma indicates that they were used in sequence. AZT, zidovudine; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; HET, heterosexual transmission; IDV, indinavir; MSM, man who has sex with men; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir; TF, transfusion; 3TC, lamivudine.
a Therapy regimen before initiation of HAART (combination therapy or monotherapy). Paque (Amersham Pharmacia Biotech). PBMC were exposed to magnetic beads (Dynabeads M-450 CD8; Dynal) to deplete the CD8 + cells and then stimulated with anti-CD3 monoclonal antibody at a concentration of 1 mg/mL in complete medium for 3 days. PBMC were then cultured in complete medium supplemented with 20 U/mL recombinant human interleukin-2 (Genzyme) for 7-10 days. Cell-free supernatant was stored in aliquots at 2 80 C. The V3 region of the isolated virus and proviral DNA from PBMC were sequenced to determine whether the isolate represented a major genotype in the quasi species in peripheral blood [21] . The TCID 50 of all virus stocks was determined using HeLa-CD4 + /long terminal repeat-b-galactosidase/CCR5 (MAGI/CCR5) cells, following the method of Reed and Muench [26] . All primary isolates were able to infect MAGI/CCR5 cells. The concentration of p24 and the TCID 50 for each isolate is given in table 1.
Neutralization assays. We used MAGI/CCR5 cells and chemiluminescent assay (Galacto-Star; TROPIX) for b-galactosidase detection to determine the neutralization activity of IgG against HIV-1. The advantages of this assay system, compared with the standard PBMC assay, are that infection of cells can be detected within 48 h [27, 28] , that the detection of b-galactosidase is more sensitive than with other methods [29] , and that the infectivity of a primary isolate remains stable in different experiments (data not shown). To rule out the influence of plasma factors, such as antiviral drugs, cytokines, or chemokines, on neutralization activity, we used IgG from patients' plasma, purified by use of protein A sepharose (Affi-gel Protein A; Bio-Rad). The concentration of IgG was estimated by measurement of its optical density at 280 nm. The day before infection, MAGI/CCR5 cells were plated in 96-well microtiter plates at a density of 1 £ 10 4 cells/well. The next day, 50 mL of IgG (1 mg/mL) and 50 mL of HIV-1 in culture supernatant (500 TCID 50 ) were incubated for 30 min at 37 C in combination with 10 mg/mL DEAE-dextran (Amersham Pharmacia Biotech), and inoculations were done in triplicate. After a 48-h incubation period, we tested for b-galactosidase activity, using the Galacto-Star system according to the manufacturer's instructions. The luminescence in each well was measured for 1 s. In each assay, we used 5 IgG samples obtained from seronegative persons as control samples without neutralization activity. The percentage of neutralization activity was calculated by the formula ½1 ÿ ðt ÿ cÞ=ðn ÿ cÞ £ 100, where t is luminescence for the test sample, c is background luminescence in absence of the virus, and n is the mean luminescence for 5 samples from seronegative volunteers.
Statistical analysis. We used IgG obtained from 5 seronegative persons as the control sample for neutralization activity against HIV-1 from each patient. No significant difference was observed in the luminescence of control samples and the luminescence of infected MAGI/CCR5 cells in the absence of IgG (data not shown). A significant difference (P , :05, by Student's t test) in the neutralization activity of patients' IgG and of control samples indicated a significant level of neutralization activity.
The correlation between neutralization activity and clinical parameters (e.g., CD4
+ cell count, CD8 + cell count, and virus load) was evaluated with Pearson's correlation coefficient. We divided patients into 4 groups (patients 1 and 2, 3-13, 14-16, and 17-19), based on neutralization activities at the initiation of HAART and at the end of the study. To determine whether HIV-specific CD4 + T cell frequencies among the 4 groups of subjects were statistically different, we used the Kruskal-Wallis test. For all statistical tests, a 2-tailed P value of .05 was considered to be significant.
Results
Characteristics of the neutralization assay. We used MAGI/CCR5 cells and the chemiluminescent assay system for detection of b-galactosidase to determine the neutralization activity of IgG against HIV-1. We compared the standard PBMC blast assay with the MAGI/CCR5 assay, using the same primary isolate (KMT), to evaluate the sensitivity of this assay system. In contrast to the results of the PBMC blast assay, luminescence correlated linearly with TCID 50 (P , :001, data not shown) in the MAGI/CCR5 assay. We observed a logarithmic association between reduction in p24 production and reduction in luminescence (data not shown). A 50% reduction in luminescence corresponded to a 70% reduction in p24 production. To evaluate the reliability of the MAGI/CCR5 assay, the neutralization activities of antibodies RC25 and Cb1 and of IgG from seronegative volunteers against laboratory isolates JR-FL and NL4-3 were measured (data not shown). In both experiments, specific neutralization activities were observed at a very low concentration (0.4 mg/mL). Significant neutralization activity was never observed with any concentration of IgG. These results were identical to the characteristics of each antibody demonstrated on standard PBMC assay.
Longitudinal change of neutralization activity against an autologous isolate. To evaluate the functional immune reconstitution against HIV-1 in a patient undergoing HAART during chronic infection, we investigated the longitudinal change in neutralization activity against an autologous isolate, using a series of IgG samples obtained before and during HAART (figure 1). The levels of neutralization activity found in patients were watched for 12-31 months after the initiation of HAART. A significant difference (P , :05, by Student's t test) in the level of neutralization activity of IgG from each patient and that of 5 IgG samples obtained from 5 seronegative persons indicated a significant level of neutralization activity. The level of significance of the development of neutralization activity was determined by use of Student's t test to compare activity at the initiation of HAART with activity at the end of the observation period for each patient. For all statistical tests, a 2-tailed P value of .05 was considered to be significant. Thirteen of 19 patients (patients 1-13) had significant levels of neutralization activity at the initiation of HAART. We observed relatively high levels of neutralization activity (>50%) in patients 1 and 2 at study entry, and these levels of activity were sustained during HAART. Significant but relatively low levels of neutralization activity (,50%) were observed in 11 of 13 patients (patients 3-13) at initiation of HAART. In patient 5, neutralization activities significantly increased during HAART (10:2%4 :1% [mean^SD] at initiation; 45:6%^3:9% at 20 months; P , :001). Levels of neutralization activity were relatively low in patients 3, 4, and 6-12 during HAART. A reduction in activity was observed only in patient 13. No significant levels of neutralization activity were detected in the remaining 6 patients (patients 14-19) at initiation of HAART. However, surprisingly, the development of significant neutralization activity against autologous isolates was observed in 3 patients (patients 17-19) after prolonged suppression of viremia by HAART. Patient 17 developed activity at 12 months after the initiation of HAART, and this activity was maintained for .12 months. Patients 18 and 19 had increased activity at 17 and 18 months after initiation of HAART, and the level of activity remained stable, even after 21 and 25 months, respectively. In these 3 patients, we determined the level of neutralization activity of IgG at a concentration (100 mg/mL) 5-fold lower than that used in the standard assay. At that concentration, the level of neutralization activity was generally lower, but the tendency toward development of neutralization activity was the same as was noted at a concentration of 500 mg/mL of IgG (data not shown). In 3 patients (patients 14-16), neutralization activity did not develop during the follow-up period.
In summary, 4 of 19 patients showed reconstitution or increase in neutralization activity during HAART, whereas levels of activity in most patients were more or less unchanged.
Correlation of neutralization activity with clinical indices. We examined the clinical characteristics of 3 patients in whom neutralization activity developed during HAART. The number of CD4 + cells increased in patients 17 and 18 during HAART (increase of 10.3 and 10.7 cells/mL/month, respectively). For patient 19, the increase in CD4 + cell count was moderate (increase of 2.7 cells/mL/month). Autologous neutralization titers were found to develop or increase temporarily in association with viremic outbursts in 3 patients who received HAART intermittently [16] . In our patients 17 and 19, there was a single episode of low-level viral rebound (a "blip") during the period of HAART. Patient 5, the only patient who had preexisting neutralization activities that increased during HAART, experienced blips. Patients 10, 15, and 16 also had blips; however, no significant increase in neutralization activities was observed in these 3 patients.
To investigate the correlation between neutralization activities and clinical indices, we classified the patients into 4 groups (patients 1 and 2, 3-13, 14-16, and [17] [18] [19] , according to the level of neutralization activity at the initiation of HAART and at the end of this study. However, there was no significant correlation between level of neutralization activity and change in CD4 + cell counts or change in virus load during HAART among these groups (data not shown). Some studies have suggested that HIV-specific CD4 + T cells play an important role in control of HIV-1 [5, 30] . We investigated the antigenspecific CD4 + T cell response to HIV-1 (JR-FL) lysate by use of intracellular cytokine staining assay and flow cytometry (table 2) . In many patients, we detected a low frequency of HIV-1-specific CD4 + T cells, but those that were present produced interferon-g, interleukin-4, or both in response to JR-FL antigen. We found no significant correlation between levels of neutralization activity and HIV-specific CD4 + T cell frequencies in these 4 groups of patients (P ¼ :95).
Because general recovery of the immune system is associated with an increase in CD4 + cell counts [4, 30] , we compared levels of neutralization activity with absolute CD4 + cell counts (figure 2). A correlation was seen between neutralization activity and CD4 + cell count at the time of the neutralization assay (r 2 ¼ :07; P , :005). No correlation was observed for CD8 + cell counts and plasma virus load at the time of the neutralization assay (data not shown).
Characteristics of neutralizing antibodies in patients 17 and 19. To investigate the characteristics of the neutralizing antibody that developed in patients 17 and 19, we measured neutralization activity against laboratory isolates, using IgG from patients (figure 3). We used autologous primary isolate NL4-3 (panel for X4 virus) and SF162 (panel for R5 virus) and tested 5 patients: patient 2, who maintained relatively high neutralization activity during HAART; patient 8, who had relatively high neutralization activity during HAART temporarily; patients 17 and 19, who developed neutralization activity during HAART; and the patient with LTNP. Patients 2 and 8 showed cross-neutralization activities against both NL4-3 and SF162; this cross-reactivity was similar to that of the patient with LTNP. In contrast, significant activity against SF162, but not NL4-3, Reconstitution of Neutralizing Antibody JID 2002;185 (1 January) was observed in patients 17 and 19. These results indicate that reconstituted neutralization activity differs from activity that developed before the initiation of HAART.
We measured the binding activity of patients' plasma to recombinant gp120 of NL4-3 or SF162 and synthetic peptides identical for the V2 or V3 region of the primary isolates longitudinally in patients 17 and 19 to investigate epitopes of the newly developed antibodies (data not shown). In both patients, the binding activities to monomeric gp120 or synthetic peptides were not strong and tended to decline during HAART.
Discussion
Humoral immunity against HIV-1 infection has been reported [12, 16, 17, 31] . In many of these studies, heterologous or laboratory isolates have been used in the neutralization assay [32, 33] . However, such experiments will not predict neutralization activity against HIV-1 proliferation in infected persons [17] .
We investigated the longitudinal change in levels of neutralizing antibodies against autologous HIV-1 in patients undergoing HAART during chronic infection. We observed significant neutralization activity against autologous isolates in 13 of 19 patients who were chronically infected before initiation of HAART (figure 1). Eleven of 13 showed significant but relatively low levels of neutralization activity, and the remaining 2 patients had high activity at initiation of HAART. These results are in accord with observations made elsewhere that neutralization activity against autologous isolates is generally weak in subjects with chronic infection [12, 13, 16] .
Binding antibody titers against HIV-1 antigens have been examined in the cases of chronically infected patients who are undergoing HAART. What effect HAART has on binding activity is controversial. Binley et al. [16] reported that 7 of 11 patients in their study showed little or no change in anti-gp120 titers after the initiation of HAART. Morris et al. [19] reported that anti-gp120 and anti-p24 titers declined in almost all patients during HAART in their study. When we compared levels of neutralization activity in patients who had significant activity at the start of HAART, most patients sustained activity at a level similar to the baseline seen during HAART.
We also observed a significant development of neutralization activity in 3 of 6 patients who did not have such activity at initiation of HAART (patients 17-19; figure 1) . Binley et al. [16] reported that autologous neutralization titers developed or increased to unusually high levels in association with viremic outbursts in 3 of 4 patients for whom HAART was administered intermittently during primary infection. In our study, 3 of 4 patients (patients 5, 17, and 19) in whom an increase in or reconstitution of neutralizing activity was seen had blips.
Blankson et al. [34] reported that patients who received optimal HAART and who had low CD4 + cell count nadirs had detectable p24-specific T cell proliferative responses, and they suggested that patients with very low CD4 + cell count nadirs would be more likely to undergo significant thymic regeneration, peripheral expansion of naive cells, or both. In our study, 4 of 6 patients (patients 5 and 17-19) who had relatively low CD4 + cell counts (,200 cells/mL) at the start of HAART and had prolonged virus suppression during HAART had either development of or an increase in neutralizing antibodies against autologous isolates. The development of this neutralization activity was detected at .12 months after initiation of HAART for patients [17] [18] [19] . This period corresponds to the period of recovery of the CD4 + naive subset [32] and HIV-1-specific CD4 + T cells [35] , which have an important role in the development of antigen-specific humoral immunity [36] . We detected HIVspecific CD4 + T cells at the end of the study in these subjects, although at low frequencies (table 2) . Further analysis of reconstituted antibodies against 2 laboratory isolates suggests that these antibodies have limited cross-reactivity (figure 3). In cases of primary infection, neutralization antibodies against autologous isolates are detected 12 months after seroconversion, and the antibodies are highly specific for the virus present during the early phase of HIV infection [17] . Reconstituted antibodies have some similarity to antibodies seen in cases of primary infection. It may be that both prolonged virus suppression with very low CD4 + cell count nadirs (for subsequent recovery of CD4 + naive cells) and HIV-specific CD4 + T cells and blips (for the stimulation of the immune system) in vivo are required to develop neutralization activity against autologous isolates.
Despite the reconstitution of neutralization activity, binding activities to monomeric gp120 and linear epitopes of synthetic peptides were relatively weak and were reduced during HAART in patients 17 and 19 (data not shown), which is consistent with data from Morris et al. [19] . To further examine discrepancies between neutralization and binding activities, we measured the inhibition activity of monomeric gp120 and synthetic peptides in a neutralization assay, with use of combinations of IgG samples and autologous isolates from each patient. However, none showed inhibition activities (data not shown). These results suggest that reconstituted antibodies are not detectable in a binding assay that uses recombinant gp120 or synthetic peptides. In line with a report that many neutralizing antibodies that develop in vivo are directed at conformational epitopes [37] , reconstituted antibodies may recognize conformational-dependent epitopes of gp120 in a native trimer form.
When we classified 19 patients into 4 groups according to neutralization activity at the initiation of HAART and at the end of this study, we found no correlation between these activities and clinical indices. These findings may relate to differences in the therapy regimen and responses to therapy among the patients. We found no significant correlation between neutralization activity and HIV-specific CD4 + T cell frequency among those 4 groups (table 2) . However, CD4 + T cell count at the time that the neutralization assay was done was significantly associated with the level of neutralization activity (figure 2). Correlations between HIV-specific CD4 + T cell and neutralization activity will become clearer if a more sensitive system for detecting HIV-specific CD4 + T cell function is available. Neutralizing antibody responses against autologous isolates recovered in those of our patients who received HAART during chronic infection. Although the precise mechanism of reconstitution of immune responses against HIV-1 antigens is unclear, long-term suppression of viral replication and general recovery of CD4 + T cells or B cells may be important for development of neutralizing antibodies in vivo.
